top of page

Take a look at some of our published work

Estimating health state utilities for aromatic L-amino acid decarboxylase deficiency (AADCd) in the United States

Monteleone, B., Forster, K., Chua, G.N. et al. Estimating health state utilities for aromatic L-amino acid decarboxylase deficiency (AADCd) in the United States. Health Qual Life Outcomes 23, 7 (2025).

Caregiver burden associated with caring for individuals with tuberous sclerosis complex-associated seizures: A descriptive, non-interventional survey in Sweden

Siu Hing Lo, Hanna Skrobanski, Miranda Harrison, Jamshaed Siddiqui, Sally Bowditch

Using the EQ-5D to measure caregiver health-related quality of life in rare pediatric disease: a study in aromatic L-amino acid decarboxylase deficiency

Acaster, S., Williams, K., Skrobanski, H., Buesch, K. (2022). Using the EQ-5D to measure caregiver health-related quality of life in rare pediatric disease: a study in aromatic L-amino acid decarboxylase deficiency. Future Neurology, 17, 2.

Symptoms and impacts of aromatic L-amino acid decarboxylase (AADC) deficiency among individuals with different levels of motor function

Williams K., Skrobanski, H., Buesch, K., Acaster, S. (2022). Symptoms and impacts of aromatic l-amino acid decarboxylase (AADC) deficiency among individuals with different levels of motor function. Orphanet J Rare Dis, 17: 128.

Exploring Health-Related Quality of Life Burden in Peanut Allergy and the Potential Benefit of Oral Immunotherapy: Estimation of Health State Utility Values for Children and Adolescents and Their Caregivers

Gallop, K. Acaster, S., de Vries, J., Browne, R., Ryan, R., Bker, S., Du Toit, G. (2022). Exploring Health-Related Quality of Life Burden in Peanut Allergy and the Potential Benefit of Oral Immunotherapy: Estimation of Health State Utility Values for Children and Adolescents and Their Caregivers. Patient Preference and Adherence, 16, 1269-1278.

Plate of peanuts

Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom

Lo, SH., Gorni, K., Sutherland, CS., Marti, Y., Lloyd, AJ., Paracha, N. (2022). Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom. Pharmacoeconomics, 40, 91-102.

Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries

Lo, SH., Lawrence, C., Gorni, K., Sutherland, CS., Marti, Y., Lloyd, AJ., Paracha, N. (2022). Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom. Pharmacoeconomics, 40, 91-102.

Get in touch for bespoke solutions

Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States

Lo, SH., Lloyd, AJ., Elkhalifa, S., Sisic, Z., van Nooten, FE. (2022). Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States. Pharmacoeconomics Open, 6, 231-239.

Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex

Lo, SH., Marshall, J., Skrobanski, H., Lloyd, A. (2022). Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex. Pharmacoeconomics Open, 6, 105-121.

The EQ-5D and the EuroQol Group

Lloyd AJ & Pickard SA. (2019). Value in Health, 22(1), 21-22.

Symptoms and impacts of ambulatory nonsense mutation Duchenne muscular dystrophy: a qualitative study and the development of a patient-centred conceptual model

Williams K., Davidson, I., Rance, M., Boehnke, A., Buesch, K., Acaster, S. (2021). Symptoms and impacts of ambulatory nonsense mutation Duchenne muscular dystrophy: a qualitative study and the development of a patient-centred conceptual model. Journal of Patient-Reported Outcomes.

Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report

Brazier J, Ara R, Azzabi I ... Lloyd AJ, Paisley MA & Pickard SA. (2019). Value in Health, 22(3), 267-275.

Patient reported outcome and observer reported outcome assessment in rare disease trials

Acaster, S. (2017) Value in Health, 20(7)

Special Edition on Utility Measurement

Lloyd, AJ PharmacoEconomics (2017). 35(Suppl 1): 5

Man and woman focusing on work

Leffler D, Acaster S, Gallop K, Dennis M, Adelman D. (2017) Value in Health

A novel patient-derived conceptual model of the impact of coeliac disease in adults: Implications for patient-reported outcome and health-related quality of life instrument development

Social preference weights for treatments in Fabry disease in the UK: a discrete choice experiment

Lloyd AJ, Gallop K, Ali S, Hughes D & MacCulloch A. (2017) Current medical research and opinion, 33(1), 23-29

EQ-5D: Moving from Three Levels to Five

Lloyd AJ Value Health 2018 21, 57–58

3

Read our newsletter: Notes by Acaster Lloyd

bottom of page